Vergelijking

Icatibant vs. Nafarelin

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

138614-30-9

geen gegevens

Molecuulmassa

1304.52 g/mol

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Nafarelin

Nafarelin is a potent GnRH agonist: after an initial stimulation ('flare'), continuous receptor occupancy leads to downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Icatibant	Nafarelin
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Icatibant

Volledige vermelding →

Nafarelin

Volledige vermelding →

Frequently asked questions

What is the difference between Icatibant and Nafarelin?: Icatibant is classified as "Onderzoek (overig)", while Nafarelin is classified as "Onderzoek (overig)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Nafarelin: Nafarelin is a GnRH agonist and the only member of this class delivered as a nasal spray. It is approved for treating endometriosis and central precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Nafarelin?: The highest available evidence level is "Humane RCT" for Icatibant and "Humane RCT" for Nafarelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Nafarelin in Germany and the United States?: Duitsland: Icatibant — Op recept, Nafarelin — Op recept. Verenigde Staten: Icatibant — Op recept, Nafarelin — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Nafarelin

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Icatibant and Nafarelin?

Icatibant is classified as "Onderzoek (overig)", while Nafarelin is classified as "Onderzoek (overig)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Nafarelin: Nafarelin is a GnRH agonist and the only member of this class delivered as a nasal spray. It is approved for treating endometriosis and central precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Nafarelin?

The highest available evidence level is "Humane RCT" for Icatibant and "Humane RCT" for Nafarelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Nafarelin in Germany and the United States?

Duitsland: Icatibant — Op recept, Nafarelin — Op recept. Verenigde Staten: Icatibant — Op recept, Nafarelin — Op recept. These are factual summaries with source and review date on the individual pages.